A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma.
Clin Exp Dermatol
; 41(3): 267-71, 2016 Apr.
Article
in En
| MEDLINE
| ID: mdl-26411345
ABSTRACT
We report three cases of skin toxicity associated with oral mitogen-activated protein kinase kinase (MEK) inhibitor treatment for metastatic malignant melanoma (MM). All three patients developed oedema, and a single patient experienced eyelash trichomegaly. This is the first known report of eyelash trichomegaly secondary to MEK inhibitor use. We also discuss possible mechanisms for MEK inhibitor-associated oedema development. This series supports the role of the dermatologist in the screening and management of patients in the rapidly developing oncology setting, as new targeted agents can give rise to marked skin toxicity.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Diseases
/
Skin Neoplasms
/
Acrylonitrile
/
Mitogen-Activated Protein Kinase Kinases
/
Protein Kinase Inhibitors
/
Edema
/
Aniline Compounds
/
Melanoma
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Exp Dermatol
Year:
2016
Document type:
Article
Affiliation country:
Reino Unido